BI 894999 First in Human Dose Finding Study in Advanced Malignancies
Status:
Active, not recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This study is open to adults with different types of advanced cancer (solid tumours). The
study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment
was not successful. In some countries, adolescents who are at least 15 years old and who are
diagnosed with NUT carcinoma can also participate. No standard treatment exists for this rare
and aggressive form of cancer.
The purpose of this study is to find out the highest dose of BI 894999 that people can
tolerate.
BI 894999 is tested for the first time in humans. Participants take tablets once daily. The
study also tests whether participants can tolerate BI 894999 better when taken continuously
or with breaks in between.
Participants can stay in the study as long as they benefit from the treatment and can
tolerate it.
The doctors also regularly check the general health of the participants.